Big Pharma has too much control |
|
|
|
|
GIVE NOW to Help Lower Soaring
Drug Prices!
|
|
|
|
Dear John,
|
Little time remains in the current session of Congress to rein in the soaring cost of prescription drugs — and bring seniors real relief in their wallets.
Lawmakers have mere weeks to take care of business before all the attention turns to the presidential election and adjourning for the year. And so, we must do all we can to make lowering prescription drug costs a top priority for our lawmakers now, this year — because I assure you, the forces working to stop passage of legislation that would hold Big Pharma accountable for their ruthless drug pricing policies are working just as hard to defeat these bills.
John, the status quo simply cannot stand with it comes to drug prices! Medicare beneficiaries' average out-of-pocket costs for certain brand name drugs rose by 40% between 2011 and 2015. Seniors, especially those living on fixed incomes, are experiencing real hardship caused by Big Pharma's greed. That's why the National Committee supports allowing the Medicare program to negotiate directly for drugs and to provide the program with meaningful tools to encourage manufacturers to price products fairly.
The National Committee also supports policies that would lower drug costs for all drugs, not just those used by Medicare beneficiaries. And we urge Congress to enact reforms that would reduce expansive patent and regulatory marketing monopolies to allow generic drug competitors to come to market sooner and drive down drug costs.
The National Committee is counting on your immediate help to give our advocacy efforts on Capitol Hill a much-needed final push before lawmakers head home to their districts and states. As always, the support we receive from informed Americans like you gives us clout in Washington to effectively fight against painful hikes in prescription drug costs and expose the greed of Big Pharma. Together, we will demand fair prescription drug prices!
|
|
Sincerely, |
|
Max Richtman
President & CEO
|
|
|
|
|
|
|
|
|
|
|